Miguel Sanz

Summary

Affiliation: University of Valencia
Country: Spain

Publications

  1. doi request reprint Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
    Javier de la Serna
    Hospital 12 de Octubre, Madrid, Spain
    Blood 111:3395-402. 2008
  2. ncbi request reprint Conventional induction and post-remission therapy in APL: have we arrived?
    Miguel A Sanz
    Hospital Universitario La Fe and Department of Medicine of the Universitat de Valencia, Valencia, Spain Electronic address
    Best Pract Res Clin Haematol 27:33-8. 2014
  3. pmc The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature
    Pau Montesinos
    Hematology Department University Hospital La Fe, Valencia, Spain
    Mediterr J Hematol Infect Dis 3:e2011059. 2011
  4. pmc Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination
    Rafael Rojas
    The Departments of Hematology and Stem Cell Transplantation Units of University Hospital Reina Sofia, Cordoba Spain
    Mediterr J Hematol Infect Dis 4:e2012011. 2012
  5. doi request reprint Acute promyelocytic leukemia: do we have a new front-line standard of treatment?
    Miguel A Sanz
    Oncology and Hematology Department, University Hospital La Fe, Torre F, Planta 7, Bulevar Sur S N, 46026, Valencia, Spain
    Curr Oncol Rep 15:445-9. 2013
  6. pmc Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain
    Santiago Grau
    Hospital del Mar, Barcelona, Spain
    BMC Infect Dis 12:83. 2012
  7. ncbi request reprint Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation
    M A Sanz
    Hematology Service, Hospital Universitario La Fe, Valencia, Spain
    Bone Marrow Transplant 39:461-9. 2007
  8. ncbi request reprint Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial
    Miguel A Sanz
    Servicio de Hematologia, Hospital Universitario La Fe, Av Campanar 21, 46009 Valencia, Spain
    J Antimicrob Chemother 50:79-88. 2002
  9. ncbi request reprint Practice points, consensus, and controversial issues in the management of patients with newly diagnosed acute promyelocytic leukemia
    Miguel A Sanz
    Hematology Service, University Hospital La Fe, Valencia, Spain
    Oncologist 10:806-14. 2005
  10. ncbi request reprint Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence
    Miguel A Sanz
    University Tor Vertgata, Rome
    Haematologica 90:1231-5. 2005

Detail Information

Publications76

  1. doi request reprint Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
    Javier de la Serna
    Hospital 12 de Octubre, Madrid, Spain
    Blood 111:3395-402. 2008
    ..These data furnish clinically relevant information that might be useful for designing more appropriately risk-adapted treatment protocols aimed at reducing the considerable problem of induction mortality in APL...
  2. ncbi request reprint Conventional induction and post-remission therapy in APL: have we arrived?
    Miguel A Sanz
    Hospital Universitario La Fe and Department of Medicine of the Universitat de Valencia, Valencia, Spain Electronic address
    Best Pract Res Clin Haematol 27:33-8. 2014
    ....
  3. pmc The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature
    Pau Montesinos
    Hematology Department University Hospital La Fe, Valencia, Spain
    Mediterr J Hematol Infect Dis 3:e2011059. 2011
    ....
  4. pmc Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination
    Rafael Rojas
    The Departments of Hematology and Stem Cell Transplantation Units of University Hospital Reina Sofia, Cordoba Spain
    Mediterr J Hematol Infect Dis 4:e2012011. 2012
    ..001) in multivariate analysis. Our results suggest that comparable outcomes can be achieved with ACT in high risk hematological patients with proven or probable IMI, whatever the combination of antifungal agents used...
  5. doi request reprint Acute promyelocytic leukemia: do we have a new front-line standard of treatment?
    Miguel A Sanz
    Oncology and Hematology Department, University Hospital La Fe, Torre F, Planta 7, Bulevar Sur S N, 46026, Valencia, Spain
    Curr Oncol Rep 15:445-9. 2013
    ....
  6. pmc Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain
    Santiago Grau
    Hospital del Mar, Barcelona, Spain
    BMC Infect Dis 12:83. 2012
    ..The perspective was that of the Spanish National Health Service (NHS)...
  7. ncbi request reprint Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation
    M A Sanz
    Hematology Service, Hospital Universitario La Fe, Valencia, Spain
    Bone Marrow Transplant 39:461-9. 2007
    ..Female recipient, a female donor to male recipient and transplants performed before 1997 were associated with decreased RI. In conclusion, HSCT still appears to have a role in APL, especially for patients in CR2...
  8. ncbi request reprint Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial
    Miguel A Sanz
    Servicio de Hematologia, Hospital Universitario La Fe, Av Campanar 21, 46009 Valencia, Spain
    J Antimicrob Chemother 50:79-88. 2002
    ..The aim of this study is to evaluate the efficacy and safety of cefepime plus amikacin compared with piperacillin-tazobactam plus amikacin for initial empirical treatment of fever in adult haematology patients with severe neutropenia...
  9. ncbi request reprint Practice points, consensus, and controversial issues in the management of patients with newly diagnosed acute promyelocytic leukemia
    Miguel A Sanz
    Hematology Service, University Hospital La Fe, Valencia, Spain
    Oncologist 10:806-14. 2005
    ....
  10. ncbi request reprint Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence
    Miguel A Sanz
    University Tor Vertgata, Rome
    Haematologica 90:1231-5. 2005
    ....
  11. ncbi request reprint Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemia
    Miguel A Sanz
    Haematology Service, University Hospital La Fe, Valencia, Spain
    Best Pract Res Clin Haematol 16:433-51. 2003
    ..As for maintenance therapy, once demonstrated, the advantage of using ATRA with or without low-dose methotrexate and 6-mercaptopurine has encouraged most groups to incorporate such treatment into their protocols for APL...
  12. ncbi request reprint [Monotherapy with meropenem in febrile granulocytopenic patients]
    M A Sanz
    Servicio de Hematologia, Hospital Universitario La Fe, Valencia
    Enferm Infecc Microbiol Clin 15:69-72. 1997
    ..Related adverse events were also similar in both groups. These studies confirm that monotherapy with meropenem is as effective as ceftazidime-containing regimens for the empiric treatment of fever in granulocytopenic patients...
  13. ncbi request reprint Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia
    Miguel A Sanz
    Hematology Service, University Hospital La Fe, Valencia, Spain
    Haematologica 90:840-5. 2005
    ....
  14. ncbi request reprint Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group
    Miguel A Sanz
    Servicio de Hematologia, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain
    Blood 103:1237-43. 2004
    ..A risk-adapted strategy combining anthracycline monochemotherapy and ATRA for induction and consolidation therapy of newly diagnosed APL results in improved antileukemic efficacy and a high degree of compliance...
  15. ncbi request reprint Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia
    Miguel A Sanz
    Servicio de Hematologia, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain
    Blood 105:3019-25. 2005
    ....
  16. doi request reprint Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
    Miguel A Sanz
    Hospital Universitario La Fe, Valencia, Spain
    Blood 112:3130-4. 2008
    ..04, respectively). This updated analysis confirms the high antileukemic efficacy, low toxicity, and high degree of compliance of a risk-adapted strategy combining ATRA and anthracycline monochemotherapy for consolidation therapy...
  17. ncbi request reprint Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
    Miguel A Sanz
    University Hospital La Fe, Valencia, Spain
    Blood 113:1875-91. 2009
    ..Finally, the approach to special situations is also discussed, including management of APL in children, elderly patients, and pregnant women...
  18. ncbi request reprint FLT3 inhibition as a targeted therapy for acute myeloid leukemia
    Miguel Sanz
    Hematology Service, University Hospital La Fe, Valencia, Spain
    Curr Opin Oncol 21:594-600. 2009
    ....
  19. ncbi request reprint A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group
    M A Sanz
    Servicio de Hematologia, Hospital Universitario La Fe, Valencia, Spain
    Blood 94:3015-21. 1999
    ..These results also suggest a minor role for cytarabine and etoposide in the treatment of newly diagnosed PML/RARalpha-positive APL patients...
  20. ncbi request reprint Cutaneous promyelocytic sarcoma at sites of vascular access and marrow aspiration. A characteristic localization of chloromas in acute promyelocytic leukemia?
    M A Sanz
    Servicio de Hematologia, Hospital Universitario La Fe, Av Campanar 21, 46009 Valencia, Spain
    Haematologica 85:758-62. 2000
    ..A careful physical examination of these particular sites in the follow-up of patients at risk, as well as cutaneous biopsy and laboratory examination of suspected lesions are strongly recommended...
  21. ncbi request reprint Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups
    M A Sanz
    Hospital Universitario La Fe, Valencia, Spain
    Blood 96:1247-53. 2000
    ..Blood. 2000;96:1247-1253)..
  22. doi request reprint Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome
    Miguel A Sanz
    Hospital Universitario La Fe, Valencia, Spain
    Blood 115:5137-46. 2010
    ..Registered at http://www.clinicaltrials.gov as NCT00408278...
  23. doi request reprint Modern approaches to treating acute promyelocytic leukemia
    Miguel A Sanz
    Hematology Department, University Hospital La Fe, Avda Companar 21, Valencia, 46009 Spain
    J Clin Oncol 29:495-503. 2011
    ..In this review article, we discuss most recent advances in the treatment of patients with newly diagnosed and relapsed APL...
  24. doi request reprint Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP)
    Miguel A Sanz
    Hospital Universitario La Fe, Servicio de Hematologia, Valencia, Spain
    Value Health 14:90-6. 2011
    ..This study sought to assess the health utilities of patients with chronic ITP and to evaluate the association of change in health utility with changes in other variables, including platelet response status and bleeding events...
  25. doi request reprint Risk-adapted treatment for low- and intermediate-risk acute promyelocytic leukemia
    Miguel A Sanz
    University Hospital La Fe, Avenida Campanar 21, Valencia, Spain
    Clin Lymphoma Myeloma Leuk 10:S130-4. 2010
    ....
  26. doi request reprint Open issues on bleeding and thrombosis in acute promyelocytic leukemia
    Miguel A Sanz
    Hospital Universitario La Fe, Valencia, Spain
    Thromb Res 125:S51-4. 2010
    ..In addition to reviewing the available data on the incidence, outcome and prognostic factors of bleeding and thrombosis in APL, we discuss the current consensus and controversies on the most appropriate management of these complications...
  27. ncbi request reprint All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia
    Miguel A Sanz
    Servicio de Hematologia, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain
    Blood 104:3490-3. 2004
    ..This study confirms the high antileukemic efficacy, low toxicity, and high degree of compliance of protocols using ATRA and anthracycline monochemotherapy for induction and consolidation therapy in elderly patients...
  28. ncbi request reprint Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation
    Noemi Puig
    Hematology Service, University Hospital La Fe, Valencia, Spain
    Leuk Lymphoma 48:2367-74. 2007
    ..001). Pneumonia after ASCT is a severe complication more commonly observed in patients with myeloma and with prolonged duration of neutropenia...
  29. ncbi request reprint FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies
    Javier de la Rubia
    Hematology Service, University Hospital La Fe, Valencia, Spain
    Leuk Res 26:725-30. 2002
    ..Overall survival (OS) at 12 months was 40%. The FLAG-IDA regimen shows evident antileukemic activity in patients with high-risk myeloid malignancies with acceptable toxicity...
  30. ncbi request reprint Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation
    J de la Rubia
    Bone Marrow Transplant Unit, Hematology Service, University Hospital La Fe, Valencia, Spain
    Bone Marrow Transplant 27:21-5. 2001
    ..We consider that high-dose therapy with ASCT should be considered in those elderly patients with good performance status and without general organ impairment...
  31. ncbi request reprint Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution
    G F Sanz
    Bone Marrow Transplantation Unit, Department of Hematology, Hospital Universitario La Fe, Av. Campanar 21, 46009 Valencia, Spain
    Bone Marrow Transplant 27:693-701. 2001
    ..These preliminary results suggest that UD-CBT may be considered a reasonable alternative in adults with CML who lack an appropriate bone marrow donor...
  32. ncbi request reprint Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell transplantation in first complete remission
    J de la Rubia
    Bone Marrow Transplant Unit, Hematology Service, University Hospital La Fe, Valencia, Spain
    Int J Hematol 80:168-73. 2004
    ..12) and disease-free survival (60% versus 36%; P = .1) compared favorably for group B. Our study suggests that collection of PBSC after additional intensification can result in a better outcome for AML patients who undergo ABSCT...
  33. ncbi request reprint Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético
    E Carreras
    BMT Section, Hematology Department, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Haematologica 85:530-8. 2000
    ..To analyze the results of unrelated bone marrow transplantation (UDBMT) as treatment for chronic myeloid leukemia (CML) in Spain...
  34. ncbi request reprint Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies
    G F Sanz
    Bone Marrow Transplantation Unit, Department of Hematology, and Laboratory of Molecular Biology, Department of Clinical Pathology, Hospital Universitario La Fe, Spain
    Blood 98:2332-8. 2001
    ..These preliminary results suggest that UD-CBT should be considered a reasonable alternative in young adults with hematologic malignancy and no appropriate bone marrow donor...
  35. ncbi request reprint Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA
    J M Hernandez
    Servicio de Hematologia, Hospital Universitario de Salamanca, Paseo San Vicente 58 182, 37007 Salamanca, Spain
    Haematologica 86:807-13. 2001
    ..clinical and biological presenting features; 2. disease outcome...
  36. ncbi request reprint Response to plasma exchange and steroids as combined therapy for patients with thrombotic thrombocytopenic purpura
    J de la Rubia
    Haematology Department, University Hospital La Fe, Valencia, Spain
    Acta Haematol 102:12-6. 1999
    ..The combination of PE and steroids is a well-tolerated and effective treatment of TTP, but improvements in therapy are needed to manage refractory patients...
  37. ncbi request reprint Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies
    A Carral
    Hematology Service University Hospital La Fe, Valencia, Spain
    Bone Marrow Transplant 29:825-32. 2002
    ..5 x 10(6) and 4 x 10(6) CD34+ cells/kg, respectively. Our results confirm the slower HR after ABSCT in AML, and highlight the importance of progenitor cell dose in accelerating HR after ABSCT...
  38. ncbi request reprint Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients
    J Sanz
    Hematology Department, Hospital Universitario La Fe, Valencia, Spain
    Bone Marrow Transplant 39:555-61. 2007
    ..Patients undergoing HSCT from unrelated donors and those who develop chronic extensive GVHD are especially predisposed for this complication...
  39. ncbi request reprint Infectious complications in patients undergoing unrelated donor bone marrow transplantation: experience from a single institution
    S Saavedra
    Servicio de Hematologia, Hospital Universitario La Fe, Valencia, Spain
    Clin Microbiol Infect 8:725-33. 2002
    ..To analyze the incidence and characteristics of documented infections in patients with hematologic malignancies undergoing unrelated donor bone marrow transplantation (UD-BMT)...
  40. doi request reprint Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone
    I Bosca
    Department of Neurology, University Hospital La Fe, Av Campanar 21, Valencia 46009, Spain
    Neurology 71:457-8. 2008
  41. ncbi request reprint Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia
    A Lopez
    Hematology Department, University Hospital La Fe, Avda Campanar, 21, 46009, Valencia, Spain
    Leuk Res 25:685-92. 2001
    ....
  42. ncbi request reprint Transplantation of CD34+ selected peripheral blood to HLA-identical sibling patients with aplastic anaemia: results from a single institution
    J de la Rubia
    Bone Marrow Transplant Unit, Hematology Service, University Hospital La Fe, Valencia, Spain
    Bone Marrow Transplant 36:325-9. 2005
    ..This is a promising procedure in patients with AA, resulting in a rapid hematopoietic recovery, a low transplant-related mortality, and a low incidence of GVHD...
  43. ncbi request reprint Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection
    F Moscardo
    Bone Marrow Transplant Unit, Department of Hematology, Hospital Universitario La Fe, Valencia, Spain
    Bone Marrow Transplant 27:983-8. 2001
    ..03) were statistically significant variables for the development of VOD. We conclude that CD34(+) positively selected PBSC transplantation could result in a marked reduction in the incidence of VOD after allogeneic HSCT...
  44. ncbi request reprint Variability in the levels of PML-RAR alpha fusion transcripts detected by the laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocols
    P Bolufer
    Laboratory of Molecular Biology, Department of Clinical Pathology, Hospital Universitario La Fe, Valencia, Spain
    Haematologica 86:570-6. 2001
    ..In the light of this, the Spanish group has recently designed an external quality assessment program (EQAP) of RT-PCR detection of PML-RAR, which includes a study of sensitivity of the participating laboratories...
  45. ncbi request reprint [Monitoring of minimal residual disease with the combined detection of PML/RAR alpha and RAR alpha/PML rearrangements in acute promyelocytic leukemia]
    P Bolufer
    Departamento de Biopatología Clínica, Hospital Universitario La Fe, Valencia
    Med Clin (Barc) 114:281-5. 2000
    ..This prompted us to perform both assays in parallel to monitor a group of APL...
  46. ncbi request reprint Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor?
    J de la Rubia
    Department of Hematology, La Fe University Hospital, Valencia, Spain
    Transfusion 41:106-10. 2001
    ..Data from the appearance of RBC antibodies other than ABO in patients undergoing HPC transplantation are limited...
  47. ncbi request reprint CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic Transplantation
    R Arranz
    Hematology Department, Hospital Universitario de la Princesa, Madrid, Spain
    Bone Marrow Transplant 29:205-11. 2002
    ..Regardless of CsA use, further improvement in survival was apparent with time, probably due to better skills in patient care...
  48. pmc Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
    Jose Cervera
    Hospital Universitario La Fe, Avenida Campanar, 21, 46009 Valencia, Spain
    Haematologica 95:424-31. 2010
    ..The incidence and prognostic significance of additional chromosomal abnormalities in acute promyelocytic leukemia is still a controversial matter...
  49. ncbi request reprint A study of incidence and characteristics of infections in 476 patients from a single center undergoing autologous blood stem cell transplantation
    Noemi Puig
    Hematology Service, University Hospital La Fe, Valencia, Spain
    Int J Hematol 86:186-92. 2007
    ..ASCT should be considered a low-risk procedure, although new therapeutic approaches for patients developing severe respiratory infections are still needed...
  50. doi request reprint Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy
    Daniela Cilloni
    Dept of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano, Turin, Italy
    Haematologica 93:921-4. 2008
    ..WT1 helps identify patients at high risk of relapse soon after induction chemotherapy allowing post-induction therapy in high risk patients to be intensified...
  51. doi request reprint Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression
    Eva Barragan
    Department of Medical Pathology, Hospital Universitario La Fe Valencia, Spain
    Clin Chim Acta 395:120-3. 2008
    ..Moreover, we compare the NPM1 results with those of WT1 expression to MRD assessment...
  52. ncbi request reprint Recurrent bacteremia caused by Rhodococcus equi in a non-neutropenic patient with acute myeloid leukemia in complete remission
    Ana Cid
    Haematology, Infectious Diseases and Microbiology Services, Hospital Universitario La Fe, Av Campanar 21, 46009 Valencia, Spain
    Haematologica 87:ECR03. 2002
  53. ncbi request reprint Recent advances in the treatment of APL
    Miguel A Sanz
    Clinical Hematology, Hematology Service, University Hospital La Fe, Valencia, Spain 46009
    Clin Adv Hematol Oncol 4:727-9. 2006
  54. ncbi request reprint Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study
    Miguel A Sanz
    Servicio de Hematologia, Hospital Universitario La Fe, Valencia, Spain
    Curr Med Res Opin 21:645-55. 2005
    ..However, it is not clear whether such combinations are advantageous over therapy with a broad-spectrum antibiotic...
  55. ncbi request reprint Current treatment of acute promyelocytic leukemia
    Francesco Lo Coco
    Haematologica 92:289-91. 2007
  56. ncbi request reprint Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation
    Noemi Puig
    Hematology Service, University Hospital La Fe, Valencia, Spain
    Leuk Lymphoma 47:1488-94. 2006
    ..The cumulative incidences of TRM were 25% in the CBV and 7% in the BEAM group (p = 0.02). CBV thus produced a higher incidence of SOS and TRM than BEAM in this series...
  57. ncbi request reprint Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group
    Juan J Ortega
    Servicio de Hematologia, Hospital Universitario La Fe, Avenida Campanar 21, 46009 Valencia, Spain
    J Clin Oncol 23:7632-40. 2005
    ..To analyze the simultaneous combination of all-trans retinoic acid (ATRA) and anthracycline monochemotherapy for children with acute promyelocytic leukemia (APL)...
  58. ncbi request reprint Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia
    Anna Sureda
    Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Haematologica 88:1213-20. 2003
    ..Imatinib mesylate (STI571) is a selective inhibitor of the bcr/abl tyrosine kinase with therapeutic potential in the blast crisis (BC) of chronic myelogenous leukemia (CML)...
  59. ncbi request reprint A t(17;20)(q21;q12) masking a variant t(15;17)(q22;q21) in a patient with acute promyelocytic leukemia
    Zaida Garcia-Casado
    Department of Hematology, Hospital Universitario La Fe, Avenida Campanar, 21, 46009 Valencia, Spain
    Cancer Genet Cytogenet 168:73-6. 2006
    ....
  60. ncbi request reprint Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation
    Federico Moscardo
    Hematology Department, Hospital Universitario La Fe, Avda Campanar 21, 46009 Valencia, Spain
    Exp Hematol 31:545-50. 2003
    ..However, no comparative studies have been performed to investigate this. We analyzed the influence of selection for CD34(+) cells on the incidence and severity of hepatic veno-occlusive disease (VOD)...
  61. ncbi request reprint SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor
    Armando V Mena-Duran
    Inflammatory and Infectious Disease Center, The Burnham Institute, La Jolla, CA 92037, USA
    Br J Haematol 129:791-4. 2005
    ..0021) and had shorter survival (P < 0.001). Cox regression analysis demonstrated that SHP1 expression in megakaryocytes had prognostic relevance for time to progression (P = 0.009) and overall survival (P = 0.001)...
  62. ncbi request reprint Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation
    Miguel A Diaz
    Spanish Group for Allogeneic Peripheral Blood Stem Cell Transplantation
    Haematologica 88:919-22. 2003
    ..In this study we analyzed predictive factors for PBPC collection in pediatric donors...
  63. ncbi request reprint Basal CD34(+) cell count predicts peripheral blood progenitor cell mobilization and collection in healthy donors after administration of granulocyte colony-stimulating factor
    Javier de la Rubia
    Haematologica 89:1530-2. 2004
    ..Basal CD34(+) cell count and sex were the two variables that significantly predicted a better CD34(+) cell mobilization, and greater age was the only variable associated with lower CD34+ cell yields...
  64. ncbi request reprint Cord-blood transplantation in patients with leukemia--a real alternative for adults
    Miguel A Sanz
    N Engl J Med 351:2328-30. 2004
  65. ncbi request reprint Unrelated-donor cord blood transplantation for adult hematological malignancies
    Federico Moscardo
    Bone Marrow Transplant Unit, Hematology Department, Hospital Universitario La Fe, Valencia, Spain
    Leuk Lymphoma 45:11-8. 2004
    ..Current data confirm that UD-CBT is a reasonable alternative for those patients lacking a matched bone-marrow donor...
  66. ncbi request reprint The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia
    Pascual Bolufer
    Laboratory of Molecular Biology, Department of Medical Biopathology, Hospital Universitario La Fe, Valencia, Spain
    Haematologica 92:308-14. 2007
    ....
  67. ncbi request reprint Viroporin activity of murine hepatitis virus E protein
    Vanessa Madan
    Centro de Biologia Molecular CSIC UAM, Facultad de Ciencias, Universidad Autonoma, Cantoblanco, 28049 Madrid, Spain
    FEBS Lett 579:3607-12. 2005
    ..Finally, brefeldin A powerfully blocks the viroporin activity of the E protein in BHK cells, suggesting that an intact vesicular system is necessary for this coronavirus to permeabilize mammalian cells...
  68. ncbi request reprint Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia
    Isabel Moreno
    Molecular Biology Laboratory Dept Medical Pathology, Hospital Universitario La Fe, Valencia, Spain
    Haematologica 88:19-24. 2003
    ..Recently, internal tandem duplications (ITD) and D835 mutations in FLT3 tyrosine kinase receptor have been shown to confer a bad prognosis in AML...
  69. ncbi request reprint Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes
    Pascual Bolufer
    Laboratorio de Biologia Molecular, Lab Hormonas, C Maternal Hospital Universitario La Fe, Avda Campanar 21, 46009 Valencia, Spain
    Haematologica 87:23-32. 2002
    ..The method is based on hybridization probe (HybProbe) chemistry applied in LightCycler equipment. The study group comprised 44 successive cases of pediatric acute lymphoblastic leukemia (P-ALL)...
  70. ncbi request reprint [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]
    Blanca Xicoy
    Servicio de Hematología Clínica, Institut Catala d Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    Med Clin (Barc) 126:41-6. 2006
    ....
  71. ncbi request reprint [Management of febrile neutropenic patients]
    Isidro Jarque
    Servicio de Hematologia, Hospital Universitario La Fe, Valencia, Espana
    Enferm Infecc Microbiol Clin 23:24-9. 2005
    ..In severe microbiologically documented infections, therapy should be maintained for a minimum of 14 days. Adjuvant therapy with granulopoiesis-stimulating factors is indicated in most patients...
  72. ncbi request reprint Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
    Bruce D Cheson
    Department of Hematology Oncology, Georgetown University, Lombardi Cancer Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 21:4642-9. 2003
    ..Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders...
  73. ncbi request reprint The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia
    Eva Barragan
    Molecular Biology Laboratory, Dpt Medical Pathology, Spain
    Leuk Res 31:947-53. 2007
    ..05). This study suggests that the NQO1*2 polymorphism is relevant to the patient's response to induction therapy and that GST deletions influence treatment outcome after chemotherapy, especially in male patients...
  74. ncbi request reprint Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors
    Javier de la Rubia
    Hematology Service, Hospital La Fe, Valencia, Spain
    Transfusion 42:4-9. 2002
    ..Predictive factors of the response to rHuG-CSF in normal donors have not been extensively studied...
  75. ncbi request reprint [Current indications for voriconazole in onco-hematological patients]
    Isidro Jarque
    Servicio de Hematologia, Hospital Universitario La Fe, Valencia, Spain
    Rev Iberoam Micol 24:213-6. 2007
    ..It should be kept in mind the possibility of breakthrough IFI, particularly zygomycosis, in patients treated with voriconazole for long periods...
  76. doi request reprint Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model
    Pau Montesinos
    Hematology Service, Hospital Universitario La Fe, Avenida Campanar 21, 46019, Valencia, Spain
    Haematologica 93:67-74. 2008
    ....